Pratique doxycycline maintenant

Le principe actif du tibacïne contient un cétirizine, un chlorhydrate de doxycycline et un quinolone.

Posologie

Pour le traitement des maladies parasitaires, la posologie recommandée est de 1 comprimé par jour. Pour la prévention des infections parasitaires, une dose unique de doxycycline ou de doxycycline plus de 5 fois par jour est recommandée.

Précautions

La prise de doxycycline ne doit être envisagée que lorsque l'utilisation des antipaludiques est envisagée.

Contre-indications

Ne pas associer à la prise d'antipaludiques de deuxième génération en cas de traitement prolongé ou de préparations contenant du tibaciclovir, de paludisme ou de néoplasme.

Effets secondaires possibles

Les effets indésirables de la précipitation de doxycycline par paludisme et de paludisme sont généralement légers et temporaires.

Conclusion

La doxycycline doit être utilisée correctement et sous la supervision d'un professionnel de la santé.

Vérifiez votre nom et vous recevez le traitement avant utilisation.

Abstract

A population-based cohort study using a non-inferiority analysis and a flexible questionnaire-questionnaire (RQ)-based questionnaire for bacterial vaginosis was developed to measure the effectiveness of doxycycline vaginal cycline in treating genital ulcer. The study population was divided into four groups: women who had received doxycycline vaginal cycline for vaginal ulcer therapy (group 1), the group that received doxycycline vaginal cycline and the group that received the non-concurrent doxycycline vaginal cycline (group 2). The study population consisted of 7,836 women in the first group, 7,966 in the second group and 7,837 in the third group. The average age was 63.7 ± 12.3 years and the average standard age was 53.9 ± 9.6 years. The primary outcomes were the satisfaction in having had vaginal ulcers and the mean score on the Qoliter questionnaire, the time for ulcer formation, and the number of ulcers. Overall, the groups had the following characteristics: satisfaction in having vaginal ulcers, frequency of ulcers, number of ulcers, and time for ulcers: mean score on the Qoliter questionnaire was 7.4 ± 4.4, 7.6 ± 4.1, 7.8 ± 3.2, and 7.3 ± 4.3, respectively; median time to ulcers was 3.2 ± 3.1 days and median time to ulcers was 1.8 ± 3.0 days. The group that received doxycycline vaginal cycline had significantly greater satisfaction than the group that received non-concurrent doxycycline vaginal cycline (p = 0.003). The average duration of the therapy between group was 1.8 ± 3.3 days and the average treatment between groups was significantly more effective than doxycycline vaginal cycline (p = 0.02).

Publication types